Professor, Urology, Baylor College of Medicine
Urology
Dr. Dov Kadmon, MD
|
|
Give Review
Kadmon is an expert in the field of Urology. He attended The Hebrew University of Jerusalem Hadassah Medical School. He has 5 awards "America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Doctor Dov Kadmon, MD is a published doctor. He published 100 publications, including: 'Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-contro...' He is registered with Medicare and accepts Medicare payments.
Publications
- Semaphorin 4F as a Critical Regulator of Neuroepithelial Interactions and a Biomarker of Aggressive Prostate Cancer.
- HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate Cancer.
- 2-[18F]fluoroputrescine: preparation, biodistribution, and mechanism of defluorination.
- alpha-Difluoromethylornithine enhancement of 14C-putrescine uptake by an androgen-dependent prostatic tumor.
- Percutaneous drainage of prostatic abscesses.
- Synthesis and uptake of no-carrier-added 1-[11C]putrescine into rat Prostate.
- Effect of estrogen and androgen administration on alpha-difluoromethylornithine-enhanced putrescine uptake by the rat Prostate.
- Regression of metastatic Renal cell carcinoma: a case report and literature review.
- Prostatic Cancer, acid phosphatase, creatine kinase-BB and race: a prospective study.
- Immunotherapy of superficial Bladder cancer.
- Differential effect of alpha-difluoromethylornithine on the in vivo uptake of 14C-labeled polyamines and methylglyoxal bis(guanylhydrazone) by a rat Prostate-derived t...
- Inhibition of mouse Bladder tumor proliferation by murine interferon-gamma and its synergism with interferon-beta.
- Growth inhibition of a Prostate tumor by alpha-difluoromethylornithine and by cyclophosphamide.
- Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethylornithine.
- Difluoromethylornithine enhancement of putrescine uptake into the Prostate: concise communication.
- Inhibition of the R3327MAT-Lu prostatic tumor by diethylstilbestrol and 1,2-bis(3,5-dioxopiperazin-1-yl)propane.
- Treatment of a metastatic Prostate derived tumor with surgery and chemotherapy.
- Effect of surgery and adjuvant chemotherapy on the R3327 MAT-Ly Lu tumor.
- Effect of high dose diethylstilbestrol and ICRF-159 on the growth and metastases of the R3327 MAT-LyLu Prostate-derived tumor.
- Effect of mini-dose heparin on lymphocele formation following extraperitoneal pelvic lymphadenectomy.
- Treatment with finasteride following radical prostatectomy for prostate Cancer.
- Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate Cancer.
- Mesenchymal-epithelial interactions and transforming growth factor-beta 1 expression during normal and abnormal prostatic growth.
- Association of transforming growth factor-beta 1 with prostate Cancer: an immunohistochemical study.
- Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse Prostate morphogenesis.
- Transitional cell carcinoma in a tuberculous Kidney: case report and review of the literature.
- Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse Prostate reconstitution model sy...
- Transgenic models for the study of prostate Cancer.
- Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse Prostate.
- Retroviral transduction of transforming growth factor-beta1 induces pleiotropic benign prostatic growth abnormalities in mouse Prostate reconstitutions.
- Pitfalls in interpreting Prostate specific antigen velocity.
- Intracranial metastases as the first manifestation of prostate Cancer.
- Transforming growth factor-beta localization during mouse Prostate morphogenesis and in prostatic growth abnormalities.
- A c-rasHa mutation in the metastasis of a human papillomavirus (HPV)-18 positive penile squamous cell carcinoma suggests a cooperative effect between HPV-18 and c-rasH...
- Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate Cancer: results of a randomized, double-blind, placebo-contro...
- Solitary pulmonary metastasis from prostate Cancer.
- Differential expression of nuclear retinoid receptors in normal and malignant Prostates.
- Beyond prostate specific antigen--markers for prostate Cancer for the 21st Century.
- Unilocular retroperitoneal cyst of mesothelial origin presenting as a Renal mass.
- Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate Cancer.
- Suicide gene therapy for prostate Cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene.
- Cytopathic effect of in situ gene therapy in prostate Cancer.
- Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate Cancer after radical prostatectomy.
- Fenretinide therapy in prostate Cancer: effects on tissue and serum retinoid concentration.
- Gene therapy for prostate Cancer.
- Interposition sural nerve grafting during radical retropubic Prostatectomy.
- In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate Cancer.
- Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate Cancer.
- Bilateral nerve graft during radical retropubic Prostatectomy: 1-year followup.
- Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate Cancer progression.
- Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate Cancer--a preliminary report.
- Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate Cancer patients failing radiotherapy.
- In situ gene therapy for prostate Cancer: immunomodulatory approaches.
- Bilateral nerve grafting during radical retropubic Prostatectomy: extended follow-up.
- The long-term effect of Specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial.
- Post-nerve-sparing Prostatectomy, dose-escalated intensity-modulated radiotherapy: effect on erectile function.
- The role of caveolin-1 in androgen insensitive prostate Cancer.
- Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate Cancer.
- Therapeutic targets for metastatic prostate Cancer.
- Disruption of the caveolin-1 gene impairs Renal calcium reabsorption and leads to hypercalciuria and urolithiasis.
- Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical Prostatectomy.
- Improved detection of clinically significant, curable prostate Cancer with systematic 12-core biopsy.
- Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate Cancer-interim...
- Predictors of prostate Cancer after initial negative systematic 12 core biopsy.
- Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate Cancer.
- Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate Cancer patients.
- Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate Cancer detection.
- Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate Cancer.
- Correlative evidence that prostate Cancer cell-derived caveolin-1 mediates angiogenesis.
- Preliminary report of the effect of high-dose adjuvant intensity modulated radiation therapy on the sural nerve graft for cavernosal nerve sacrifice after radical pros...
- Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after r...
- Neoadjuvant therapy followed by prostatectomy for clinically localized prostate Cancer.
- Reprint of: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in pati...
- Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate Cancer.
- Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt.
- Cancer-related axonogenesis and neurogenesis in prostate Cancer.
- CDC4 gene expression as potential biomarker for targeted therapy in prostate Cancer.
- Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate Cancer.
- Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate Cancer.
- Long-term benefits of elective radiotherapy after Prostatectomy for patients with positive surgical margins.
- Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical Prostatectomy cohort.
- Radiation therapy after radical Prostatectomy: strike early, strike hard! The case for adjuvant radiation therapy.
- The effect of statins on serum Prostate specific antigen levels in a cohort of airline pilots: a preliminary report.
- Determining prostate Cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens.
- GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate Cancer preceding r...
- Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate Cancer.
- IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate Cancer.
- Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate Cancer.
- The role of caveolin-1 in prostate Cancer: clinical implications.
- The emerging role of the PI3-K-Akt pathway in prostate Cancer progression.
- Surgical considerations in treatment of intraductal carcinoma of the Prostate.
- [Multiple giant hepatic hemangiomas].
- Chemoprevention in prostate Cancer: the role of difluoromethylornithine (DFMO).
- Transforming growth factor beta 1 as a biomarker for prostate Cancer.
- Androgen sensitivity and gene expression in ras + myc-induced mouse Prostate carcinomas.
- Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse Prostate carcinoma.
- Experimental oncogene induced prostate Cancer.
- BCG and the treatment of superficial Bladder cancer.
- Elevated plasma chromogranin-A concentrations in prostatic carcinoma.
Schools
The Hebrew University Hadassah Medical School
Jaffa Govt Hospital
Barnes Jewish Hospital
Barns Hospital
Hadassah Hospital
Washington University
Procedures Preformed
- Cystourethroscopy and Transurethral Resection of Bladder Neck
- Incontinence Sling Procedure
- Prostate Removal
- Prostatectomy With Robotic Assistance
- View All
Conditions Treated
- Bladder Cancer
- Blood in Urine (Hematuria)
- Chronic Kidney Diseases
- Elevated PSA (Prostate Specific Antigen)
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
Washington University - Barnes-Jewish Hospital -
The Hebrew University of Jerusalem Hadassah Medical School
Hospital
-
Baylor St. Luke's Medical Center -
Michael E. DeBakey Veterans Affairs Medical Center
Drug Facts
| NPI NUMBER | 1851481816 | |
| NPPES Provider LastName | KADMON | |
| NPPES Provider FirstName | DOV | |
| NPPES Provider ZIPCode | 770302348 | |
| NPPES Provider State | TX | |
| Specialty Description | Urology | |
| Total Claim Count | 458.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1851481816 |
| Last Name Of The Provider | KADMON |
| First Name Of The Provider | DOV |
| View All |
Similar Doctors
|
Dr. Omar H. Durrani, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Erwin C. Winkel III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nadeem N. Dhanani, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. William J. Graber IV, MD |
|
|
Dr. John M. Baird, MD |
|
Dr. Robert A. Renner, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ramarao M. Denduluri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John P. Laneri Jr., MD |
|
|
Dr. Hajar I. Ayoub, MD |
|
|
Dr. Guilherme Godoy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Grant P. Redrow, MD |
|
|
Dr. Daniel J. Warburton, MD
This Doctor is OpenDoctor Recommended.
|